Celltrion, Inc. (068270.KS) KSC

176,000.00

+1000(+0.57%)

Updated at October 20 01:45PM

Currency In KRW

Celltrion, Inc.

Address

23 Academy-ro

Incheon,

Korea, Republic of

Phone

82 3 2850 5000

Sector

Healthcare

Industry

Biotechnology

Employees

2391

First IPO Date

July 19, 2005

Key Executives

NameTitlePayYear Born
Jin-seok SeoCo-Chief Executive Officer & Inside Co-Chairman of the Board0N/A
Mr. Woo-Sung KeeCo-Chief Executive Officer & Internal Director01961
Mr. Hyong-Gi KimChief Executive Officer & Internal Director01965
Mr. Min-Cheol ShinDirector of Finance01971
Mr. Stephen YeumFounder0N/A
Mr. Ji-Hoon ChoiDirector of Legal Affairs01971

Description

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.